MedTrace Logo

PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma

NCT06696742 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-11-20

No results posted yet for this study

Summary

This study intends to explore whether the combination of Clostridium butyricum can improve the current situation of poor anti-PD1 treatment effect in patients with bladder cancer.

Conditions

  • Bladder (Urothelial, Transitional Cell) Cancer

Interventions

DRUG

Clostridium Butyricum Tablets

Gemcitabine and Cisplatin combined with Clostridium Butyricum Tablets

DRUG

Cisplatin

Gemcitabine and Cisplatin

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Qiang Lu · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2029-02-01
Completion
2029-02-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06696742 on ClinicalTrials.gov